Drug intelligence / Profile preview

MyeloXen

Development stage: Unknown
Lead developer: Pharmsynthez
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

MyeloXen is a vaccine developed for the treatment of Multiple Sclerosis. It is being developed by Xenetic Biosciences in collaboration with its partners SynBio and Pharmsynthez for research, development, and commercialization within Russia and the Commonwealth of Independent States (CIS). The partners are responsible for funding development activities in their territory, while Xenetic retains rights to access research data and receive royalties on approved products.

Beyond the preview

Go deeper on MyeloXen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyeloXen.

Explore the full profile